Jaguar Health(JAGX)2024-11-13 13:00Financial Performance - The combined net revenue for Q3 2024 was approximately $3.1 million, representing a 14% increase from Q2 2024 and an 11% increase from Q3 2023[1][2] - Mytesi revenue for Q3 2024 was approximately $3.0 million, up 14% from Q2 2024 and 8% from Q3 2023[4] - License revenue for Q3 2024 amounted to $42,000, with total deferred revenue from this contract at $765,000 as of September 30, 2024[5] Prescription Volume - Mytesi prescription volume increased by 10.9% in Q3 2024 compared to Q2 2024 and by 2.7% compared to Q3 2023[6] Expenses - R&D expenses decreased by $2.0 million to $4.0 million in Q3 2024, primarily due to winding down activities related to the phase 3 OnTarget clinical trial[8] - Sales and Marketing expenses increased by approximately $0.5 million to $2.0 million in Q3 2024, driven by expanded market access activities and the launch of Gelclair[9] Net Loss - Net loss attributable to common shareholders increased by approximately $2.1 million to $9.9 million in Q3 2024[11] - Non-GAAP recurring EBITDA for Q3 2024 was a net loss of $8.2 million, compared to a net loss of $6.2 million in Q3 2023[14] Product Launch and Trials - Jaguar initiated the commercial launch of Gelclair in October 2024, focusing on cancer supportive care[1][3] - The company plans to initiate two Phase 2 trials in Q4 2024 and expects results from investigator-initiated studies by the end of 2024 and throughout 2025[1][28]